An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery
Qin Huang,Ken Y. Chan,Jason Wu,Nuria R. Botticello-Romero,Qingxia Zheng,Shan Lou,Casey Keyes,Alexander Svanbergsson,Jencilin Johnston,Allan Mills,Chin-Yen Lin,Pamela P. Brauer,Gabrielle Clouse,Simon Pacouret,John W. Harvey,Thomas Beddow,Jenna K. Hurley,Isabelle G. Tobey,Megan Powell,Albert T. Chen,Andrew J. Barry,Fatma-Elzahraa Eid,Yujia A. Chan,Benjamin E. Deverman
DOI: https://doi.org/10.1126/science.adm8386
IF: 56.9
2024-05-18
Science
Abstract:Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier (BBB). BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40–50 times greater reporter expression in the CNS of human TFRC knock-in mice. The enhanced tropism was CNS-specific and absent in wild type mice. When used to deliver GBA1 , mutations of which cause Gaucher disease and are linked to Parkinson's disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared to AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.
multidisciplinary sciences